Nasdaq Markets

By Bart van Velzen:

By Bart van Velzen:

By Bart van Velzen:

By Bart van Velzen:

By Bart van Velzen:

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By Douglas McBride:Catalysts for Inovio in 2020 Inovio's flagship product (VGX-3100) for cervical dysplasia caused by HPV remains one of the primary market opportunities. Inovio expects top-line efficacy and safety data in 4th quarter 2020. This should prove to be a significant

By SA Marketplace: We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article, in case you'd like to catch up on any specific angle.

Thomas Edison once summed up the topic of innovation like this: “There’s a way to do it better — find it.” So what are the next lightbulbs to illuminate Hollywood’s marquee? The second annual Variety Digital Innovators list recognizes 12 leaders pushing the boundarie

Thomas Edison once summed up the topic of innovation like this: “There’s a way to do it better — find it.” So what are the next lightbulbs to illuminate Hollywood’s marquee? The second annual Variety Digital Innovators list recognizes 12 leaders pushing the boundarie